A Phase 4 interventional study of AR11 and Placebo in Attention Deficit Hyperactivity Disorder (ADHD), sponsored by Arbor Pharmaceuticals, Inc.. Completed at 7 sites in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2020-07-21.
Sponsored by Arbor Pharmaceuticals, Inc. (part of Azurity Pharmaceuticals) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.
Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 298th largest by enrollment of the 706 interventional ones that give a count, is one of 23 that started in 2013, is one of 148 in phase 4, and was the 363rd registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:
National Institute of Mental Health (NIMH) · Sites in United States
Ages 8–17
National Institute of Mental Health (NIMH) · Sites in United States
Ages 8–13
National Institute of Mental Health (NIMH) · Sites in United States
Ages 10–17 · Healthy volunteers
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–65
Alkermes, Inc. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
807 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 62 · Phase 2 108 · Phase 3 135 · Phase 4 148
First in 1985; this study’s year is marked. 23 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 70 across the 706 interventional studies, 115 across the 98 observational. Of the 644 that completed or were terminated, 302 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
262 of 807 have an industry lead sponsor. The 10 most frequent:
This study is registered under Arbor Pharmaceuticals, Inc., one of the names counted as Azurity Pharmaceuticals. Under that name alone:
Arbor Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; none are open to participants now.
Azurity Pharmaceuticals has 3 studies filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
34 of the studies in Attention Deficit Disorder with Hyperactivity with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759154Phase 3Otsuka Pharmaceutical Development & Commercialization, Inc.A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | 2027-05-27 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT04946253University of PittsburghSKIP for PA Study: Team and Leadership Level Implementation Support for Collaborative Care | 2026-11 |
| NCT05683756University of PittsburghOptimizing Attention and Sleep Intervention Study | 2026-12 |
| NCT07594730New York State Psychiatric InstituteBrief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems | 2026-12-01 |
Add all 34 to your calendar (.ics) → With an account.
Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a dose-optimized, randomized, double-blind, placebo-controlled crossover study in approximately 100 pediatric patients (aged 6 to 12 years) with ADHD. Eligible patients will enroll to take open-label AR11 BID and undergo dose optimization activities for 8 weeks. Patients who achieve a stable dose during the dose optimization period will continue participation and will be randomized to take double-blind medication (AR11 or placebo) orally twice daily for 1 week. At the end of each double-blind treatment period, patients will be evaluated for ADHD symptoms in a laboratory classroom setting utilizing SKAMP and PERMP assessments.
This is a dose-optimized, randomized, double-blind, placebo-controlled crossover study in approximately 100 pediatric patients (aged 6 to 12 years) with ADHD. Eligible patients will enroll in the study to take open-label AR11 twice daily and undergo dose optimization activities for 8 weeks. Patients who achieve a stable dose during the dose optimization period will continue participation and will be randomized to take double-blind medication (AR11 or placebo) orally twice daily for 1 week. At the end of the first double-blind treatment period, patients will be evaluated for ADHD symptoms in a laboratory classroom setting utilizing SKAMP and PERMP assessments. At the end of the second double blind treatment period, patients will be evaluated for ADHD symptoms in a second laboratory classroom setting utilizing SKAMP and PERMP assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AR11, administered orally, BID, for one week (crossover to placebo administration week 2)
Drug: AR11
Placebo, administered orally, BID, for one week (crossover to AR11 administration week 2)
Drug: Placebo
Also known as: amphetamine sulfate
Also known as: matching Placebo
SKAMP-Combined Scores
Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale \[SKAMP\]-combined scores measured during Laboratory Classroom Days. The SKAMP scale is a validated subjective measure of ADHD symptoms in a laboratory classroom, comprised of 13 items on which subjects are rated according to a 7 point scale (0=normal to 6=maximal impairment); maximum score 78. The SKAMP-combined score is obtained by summing the rating values for each of the 13 items, whereby the higher the SKAMP score, the greater the impairment.
Time frame: 2 hours post-dose
SKAMP-Combined Scores
Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale \[SKAMP\]-combined scores measured during Laboratory Classroom Days. The SKAMP scale is a validated subjective measure of ADHD symptoms in a laboratory classroom, comprised of 13 items on which subjects are rated according to a 7 point scale (0=normal to 6=maximal impairment); maximum score 78. The SKAMP-combined score is obtained by summing the rating values for each of the 13 items, whereby the higher the SKAMP score, the greater the impairment.
Time frame: 0.75, 4, 6, 8, 10 hours post-dose
SKAMP Subscale - Attention Scores
The SKAMP scale is a validated subjective measure of ADHD symptoms. It is comprised of 13 items (grouped under the subcategories of attention, deportment, quality of work, and compliance) on which subjects are rated according to a 7-point scale (0 = normal to 6 = maximal impairment). The SKAMP-Attention subscale score is comprised of four of the 13 items with a maximum score of 24.
Time frame: 0.75, 2, 4, 6, 8, and 10 hours post-dose
SKAMP Subscale - Deportment Scores
The SKAMP scale is a validated subjective measure of ADHD symptoms. It is comprised of 13 items (grouped under the subcategories of attention, deportment, quality of work, and compliance) on which subjects are rated according to a 7-point scale (0 = normal to 6 = maximal impairment). The SKAMP-Deportment subscale score is comprised of four of the 13 items with a maximum score of 24.
Time frame: 0.75, 2, 4, 6, 8, and 10 hours post-dose
PERM-P Scores - Number of Problems Attempted
Permanent Product Measure of Performance (PERMP) assessments measured during Laboratory Classroom Days. The PERMP is an individualized, five-page math exam consisting of 400 problems. Subjects are instructed to complete as many math problems as possible in 10 minutes. Performance is evaluated using the number of problems attempted (maximum score = 400) and the number of problems correct (maximum score = 400).
Time frame: 0.75, 2, 4, 6, 8, and 10 hours post-dose
PERM-P Scores - Number of Problems Correct
Permanent Product Measure of Performance (PERMP) assessments measured during Laboratory Classroom Days. The PERMP is an individualized, five-page math exam consisting of 400 problems. Subjects are instructed to complete as many math problems as possible in 10 minutes. Performance is evaluated using the number of problems attempted (maximum score = 400) and the number of problems correct (maximum score = 400).
Time frame: 0.75, 2, 4, 6, 8, and 10 hours post-dose
| Milestone | AR11 (1 Week) Then Placebo (1 Week) - Double Blind | Placebo (1 Week) Then AR11 (1 Week) - Double Blind |
|---|---|---|
| Started | 47 | 50 |
| Completed | 46 | 49 |
| Not completed | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale \[SKAMP\]-combined scores measured during Laboratory Classroom Days. The SKAMP scale is a validated subjective measure of ADHD symptoms in a laboratory classroom, comprised of 13 items on which subjects are rated according to a 7 point scale (0=normal to 6=maximal impairment); maximum score 78. The SKAMP-combined score is obtained by summing the rating values for each of the 13 items, whereby the higher the SKAMP score, the greater the impairment.
| units on a scale | AR11 (Amphetamine Sulfate) | Placebo |
|---|---|---|
| SKAMP-Combined Scores | 10.0 ± 8.24 | 17.8 ± 1.94 |
Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale \[SKAMP\]-combined scores measured during Laboratory Classroom Days. The SKAMP scale is a validated subjective measure of ADHD symptoms in a laboratory classroom, comprised of 13 items on which subjects are rated according to a 7 point scale (0=normal to 6=maximal impairment); maximum score 78. The SKAMP-combined score is obtained by summing the rating values for each of the 13 items, whereby the higher the SKAMP score, the greater the impairment.
| units on a scale | AR11 (Amphetamine Sulfate) | Placebo |
|---|---|---|
| 0.75 hours post-dose | 11.8 ± 10.56 | 17.3 ± 11.38 |
| 4 hours post-dose | 11.6 ± 10.04 | 19.8 ± 11.92 |
| 6 hours post-dose | 14.5 ± 10.38 | 20.2 ± 11.28 |
| 8 hours post-dose | 16.0 ± 11.76 | 22.0 ± 12.33 |
| 10 hours post-dose | 16.5 ± 11.08 | 20.8 ± 13.33 |
The SKAMP scale is a validated subjective measure of ADHD symptoms. It is comprised of 13 items (grouped under the subcategories of attention, deportment, quality of work, and compliance) on which subjects are rated according to a 7-point scale (0 = normal to 6 = maximal impairment). The SKAMP-Attention subscale score is comprised of four of the 13 items with a maximum score of 24.
| units on a scale | AR11 (Amphetamine Sulfate) | Placebo |
|---|---|---|
| 0.75 hours post-dose | 2.2 ± 2.64 | 3.4 ± 3.06 |
| 2.0 hours post-dose | 1.9 ± 2.26 | 3.4 ± 3.1 |
| 4.0 hours post-dose | 2.2 ± 2.68 | 4.0 ± 3.04 |
| 6.0 hours post-dose | 2.3 ± 2.43 | 3.6 ± 2.95 |
| 8.0 hours post-dose | 2.8 ± 2.8 | 4.1 ± 3.01 |
| 10.0 hours post-dose | 3.2 ± 3.15 | 4.0 ± 3.59 |
The SKAMP scale is a validated subjective measure of ADHD symptoms. It is comprised of 13 items (grouped under the subcategories of attention, deportment, quality of work, and compliance) on which subjects are rated according to a 7-point scale (0 = normal to 6 = maximal impairment). The SKAMP-Deportment subscale score is comprised of four of the 13 items with a maximum score of 24.
| units on a scale | AR11 (Amphetamine Sulfate) | Placebo |
|---|---|---|
| 0.75 hours post-dose | 2.1 ± 3.53 | 3.9 ± 4.82 |
| 2.0 hours post-dose | 1.6 ± 2.79 | 4.0 ± 4.58 |
| 4.0 hours post-dose | 2.1 ± 3.47 | 4.7 ± 4.86 |
| 6.0 hours post-dose | 3.1 ± 4.21 | 4.3 ± 4.51 |
| 8.0 hours post-dose | 3.5 ± 4.38 | 4.9 ± 4.8 |
| 10.0 hours post-dose | 3.1 ± 3.72 | 4.9 ± 5.21 |
Permanent Product Measure of Performance (PERMP) assessments measured during Laboratory Classroom Days. The PERMP is an individualized, five-page math exam consisting of 400 problems. Subjects are instructed to complete as many math problems as possible in 10 minutes. Performance is evaluated using the number of problems attempted (maximum score = 400) and the number of problems correct (maximum score = 400).
| number of problems attempted | AR11 (Amphetamine Sulfate) | Placebo |
|---|---|---|
| 0.75 hours post-dose | 111.6 ± 53.53 | 91.2 ± 47.35 |
| 2.0 hours post-dose | 113.4 ± 51.27 | 85.7 ± 46.66 |
| 4.0 hours post-dose | 113.2 ± 56.28 | 85.1 ± 45.89 |
| 6.0 hours post-dose | 101.3 ± 54.26 | 74.9 ± 43.08 |
| 8.0 hours post-dose | 98.2 ± 56.11 | 76.4 ± 47.74 |
| 10.0 hours post-dose | 95.2 ± 55.53 | 76.3 ± 45.27 |
Permanent Product Measure of Performance (PERMP) assessments measured during Laboratory Classroom Days. The PERMP is an individualized, five-page math exam consisting of 400 problems. Subjects are instructed to complete as many math problems as possible in 10 minutes. Performance is evaluated using the number of problems attempted (maximum score = 400) and the number of problems correct (maximum score = 400).
| number of problems correct | AR11 (Amphetamine Sulfate) | Placebo |
|---|---|---|
| 0.75 hours post-dose | 104.5 ± 54.49 | 83.9 ± 46.96 |
| 2.0 hours post-dose | 107.1 ± 53.15 | 78.9 ± 44.62 |
| 4.0 hours post-dose | 107.0 ± 57.46 | 79.9 ± 45.56 |
| 6.0 hours post-dose | 95.6 ± 55.43 | 70.5 ± 43.23 |
| 8.0 hours post-dose | 92.7 ± 57.28 | 71.5 ± 47.43 |
| 10.0 hours post-dose | 89.9 ± 55.29 | 72.3 ± 45.19 |
Collected over AE reporting occurred during the 8-week open label treatment phase (i.e. AR11 dose optimization) and the 2-week double blind phase (i.e. crossover period). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AR11 | — | 0/97 (0%) | 19/97 (19.6%) |
| Placebo | — | 0/97 (0%) | 6/97 (6.2%) |
| Event | AR11 | Placebo |
|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 4/97 | 0/97 |
| InsomniaPsychiatric disorders | 3/97 | 0/97 |
| Upper abdominal painGastrointestinal disorders | 3/97 | 0/97 |
| TachycardiaCardiac disorders | 2/97 | 3/97 |
| Mood swingsPsychiatric disorders | 2/97 | 0/97 |
| Upper respiratory tract infectionInfections and infestations | 1/97 | 2/97 |
| ContusionInjury, poisoning and procedural complications | 2/97 | 0/97 |
| Decreased weightInvestigations | 2/97 | 1/97 |
| Age, Continuous(years) | AR11 (1 Week) Then Placebo (1 Week) - Double Blind | Placebo (1 Week) Then AR11 (1 Week) - Double Blind | Total |
|---|---|---|---|
| Mean | 9.6 ± 1.97 | 9.6 ± 1.78 | 9.6 ± 1.86 |
| Sex: Female, Male(Participants) | AR11 (1 Week) Then Placebo (1 Week) - Double Blind | Placebo (1 Week) Then AR11 (1 Week) - Double Blind | Total |
|---|---|---|---|
| Female | 18 | 20 | 38 |
| Male | 29 | 30 | 59 |
| Race (NIH/OMB)(Participants) | AR11 (1 Week) Then Placebo (1 Week) - Double Blind | Placebo (1 Week) Then AR11 (1 Week) - Double Blind | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 13 | 20 | 33 |
| White | 30 | 28 | 58 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Region of Enrollment(participants) | AR11 (1 Week) Then Placebo (1 Week) - Double Blind | Placebo (1 Week) Then AR11 (1 Week) - Double Blind | Total |
|---|---|---|---|
| United States | 47 | 50 | 97 |
The record gives a start of Dec 2013, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amphetamine
Attention Deficit Disorder with Hyperactivity →